GSK chooses CROs

GlaxoSmithKline recently announced that their new strategic partners will be Paraxel and PPD. According to Outsourcing Pharma, these two will provide them with a variety of clinical development in addition to trial services. They've chosen to go with these two providers because it will allow them to work more efficiently.

Do you think this is the continuing of a new trend? Will other Pharma companies reduce the amount of partners they work with in order to streamline their services?